Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis
- 28 October 2019
- journal article
- research article
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 32 (5) , 507-513
Abstract
Background: Dupilumab, a fully human monoclonal antibody targeting the alpha subunit of IL-4 was recently approved for the treatment of moderate-to-severe atopic dermatitis (AD) in adult patients. Objective: To assess dupilumab effectiveness and safety in adults with moderate-to-severe AD in a real-life Italian multicentre retrospective cohort. Methods: Adult moderate-to-severe AD patients, referring to 39 Italian centers, received dupilumab in the context of a national patient access program. Disease assessment was performed at baseline, after 4 and 16 weeks of treatment using Eczema-Area-and-Severity-Index (EASI) score, itch and sleep numerical-rating-score (itch-NRS, sleep-NRS) and Dermatology-Life-Quality-Index (DLQI). Results: A total of 109 (71 M/38F) patients was studied. There was a significant reduction in EASI score, itch-NRS, sleep-NRS and DLQI from baseline to week 4 and a further significant decline to week 16. EASI 50, EASI75 and EASI90 were achieved by 59.6%, 28.4% and 9.3% of patients at 4 weeks and by 87.2%, 60.6% and 32.4% of them at 16 weeks, respectively. Adverse events were experienced by 19.2% (21/109) of the patients and they were all mild in intensity, being conjunctivitis the most common side effect. Conclusions: Dupilumab significantly improved disease severity, pruritus, sleep loss and quality of life with an acceptable safety profile.Keywords
This publication has 20 references indexed in Scilit:
- Consensus‐based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part IIJournal of the European Academy of Dermatology and Venereology, 2018
- Dupilumab in atopic dermatitis: rationale, latest evidence and place in therapyTherapeutic Advances in Chronic Disease, 2018
- Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical tBritish Journal of Dermatology, 2017
- Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trialThe Lancet, 2017
- An Italian multicentre study on adult atopic dermatitis: persistent versus adult-onset diseaseArchives of Dermatological Research, 2017
- Two Phase 3 Trials of Dupilumab versus Placebo in Atopic DermatitisNew England Journal of Medicine, 2016
- Drug survival for ciclosporin A in a long-term daily practice cohort of adult patients with atopic dermatitisBritish Journal of Dermatology, 2015
- Dupilumab Treatment in Adults with Moderate-to-Severe Atopic DermatitisNew England Journal of Medicine, 2014
- The eczema area and severity index (EASI): assessment of reliability in atopic dermatitisExperimental Dermatology, 2001
- Measuring health-related quality of life in patients with mild to moderate eczema and psoriasis: clinical validity, reliability and sensitivity to change of the DLQIBritish Journal of Dermatology, 1999